Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8227998 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 8 Pages |
Abstract
In addition to LAPC, to our knowledge, this is the first study to evaluate concurrent chemoradiation with ADT in high-risk RP patients. With a median follow-up of 75.3 months, this trial also represents the longest follow-up of patients treated with taxane-based chemotherapy with EBRT in high-risk prostate cancer. Concurrent ADT, radiation, and weekly paclitaxel at 40 mg/m2/week in RP patients and 60 mg/m2/week in LAPC patients is feasible and well-tolerated.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Arif M.D., Yin M.D., Alireza M.D., Steven M.D., Olga Ph.D., Benjamin M.D., Heather M.D., Christine Ph.D., Nancy M.D., Pradip M.D., Young M.D.,